Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC ...Middle East

SUZHOU, China and ROCKVILLE, Md., Oct. 23, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest clinical...

Hence then, the article about live from esmo 2023 oral report featuring latest data of pelcitoclax apg 1252 combined with osimertinib demonstrates potential as a new treatment option for tp53 and egfr mutant nsclc was published today ( Monday 23/10/2023 - 03:01 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC )

Also on site :

• Sony’s Indian Version of ‘Who Wants to Be a Millionaire?’ Hosted by Amitabh Bachchan, Adds Google Gemini as AI Guide (EXCLUSIVE)
• Help! My Wife Turned Into a Religious Zealot and Spiraled to Her Death. Then Our Problems Really Started.
• New Zodiac-Themed Energy Drink Pairs Your Sign With Your Perfect Sip